Novel Antibody-Drug Conjugate Improves Outcomes in Advanced Endometrial Cancer

AI-generated NewsSnap summary based on source reporting.
Published: 2026-11-02
Category: health
Source: VHIO (Vall d'Hebron Institute of Oncology)
Original source

A Phase III clinical trial, TroFuse-005, demonstrated that sacituzumab tirumotecan (sac-TMT), a novel antibody-drug conjugate, significantly improved disease control and survival in patients with advanced or recurrent endometrial cancer. Published in The Lancet, these results offer a potential new therapeutic option for individuals with limited treatment alternatives after prior therapies.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai